Φορτώνει......
Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry
Antibodies to first‐generation recombinant thrombopoietin (TPO) neutralized endogenous TPO and caused thrombocytopenia in some healthy subjects and chemotherapy patients. The second‐generation TPO receptor agonist romiplostim, having no sequence homology to TPO, was developed to avoid immunogenicity...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Br J Haematol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
John Wiley and Sons Inc.
2020
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7540503/ https://ncbi.nlm.nih.gov/pubmed/32311075 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16658 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|